195 related articles for article (PubMed ID: 20962092)
21. Passively administered antibody suppresses the induction of measles virus antibodies by vaccinia-measles recombinant viruses.
Galletti R; Beauverger P; Wild TF
Vaccine; 1995 Feb; 13(2):197-201. PubMed ID: 7625116
[TBL] [Abstract][Full Text] [Related]
22. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
Durbin AP; Skiadopoulos MH; McAuliffe JM; Riggs JM; Surman SR; Collins PL; Murphy BR
J Virol; 2000 Aug; 74(15):6821-31. PubMed ID: 10888621
[TBL] [Abstract][Full Text] [Related]
23. Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.
Pan CH; Valsamakis A; Colella T; Nair N; Adams RJ; Polack FP; Greer CE; Perri S; Polo JM; Griffin DE
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11581-8. PubMed ID: 16037211
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model.
Weidinger G; Ohlmann M; Schlereth B; Sutter G; Niewiesk S
Vaccine; 2001 Apr; 19(20-22):2764-8. PubMed ID: 11282186
[TBL] [Abstract][Full Text] [Related]
25. Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies.
Lech PJ; Tobin GJ; Bushnell R; Gutschenritter E; Pham LD; Nace R; Verhoeyen E; Cosset FL; Muller CP; Russell SJ; Nara PL
PLoS One; 2013; 8(1):e52306. PubMed ID: 23300970
[TBL] [Abstract][Full Text] [Related]
26. Newcastle disease virus vectored infectious laryngotracheitis vaccines protect commercial broiler chickens in the presence of maternally derived antibodies.
Yu Q; Spatz S; Li Y; Yang J; Zhao W; Zhang Z; Wen G; Garcia M; Zsak L
Vaccine; 2017 Feb; 35(5):789-795. PubMed ID: 28052812
[TBL] [Abstract][Full Text] [Related]
27. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge.
Taylor J; Pincus S; Tartaglia J; Richardson C; Alkhatib G; Briedis D; Appel M; Norton E; Paoletti E
J Virol; 1991 Aug; 65(8):4263-74. PubMed ID: 1830113
[TBL] [Abstract][Full Text] [Related]
28. Measles virus-specific CD4 T-cell activity does not correlate with protection against lung infection or viral clearance.
Pueschel K; Tietz A; Carsillo M; Steward M; Niewiesk S
J Virol; 2007 Aug; 81(16):8571-8. PubMed ID: 17553890
[TBL] [Abstract][Full Text] [Related]
29. Cell-to-Cell Measles Virus Spread between Human Neurons Is Dependent on Hemagglutinin and Hyperfusogenic Fusion Protein.
Sato Y; Watanabe S; Fukuda Y; Hashiguchi T; Yanagi Y; Ohno S
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298883
[TBL] [Abstract][Full Text] [Related]
30. A hemagglutinin-derived peptide-vaccine ignored by virus-neutralizing passive antibodies, protects against murine measles encephalitis.
El Kasmi KC; Theisen D; Brons NH; Ammerlaan W; Klingele M; Truong AT; Muller CP
Vaccine; 1999 May; 17(19):2436-45. PubMed ID: 10392626
[TBL] [Abstract][Full Text] [Related]
31. The recombinant globular head domain of the measles virus hemagglutinin protein as a subunit vaccine against measles.
Lobanova LM; Eng NF; Satkunarajah M; Mutwiri GK; Rini JM; Zakhartchouk AN
Vaccine; 2012 Apr; 30(20):3061-7. PubMed ID: 22406109
[TBL] [Abstract][Full Text] [Related]
32. C3d enhancement of neutralizing antibodies to measles hemagglutinin.
Green TD; Newton BR; Rota PA; Xu Y; Robinson HL; Ross TM
Vaccine; 2001 Oct; 20(1-2):242-8. PubMed ID: 11567770
[TBL] [Abstract][Full Text] [Related]
33.
van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
[TBL] [Abstract][Full Text] [Related]
34. Neutralizing B cell response in measles.
Bouche FB; Ertl OT; Muller CP
Viral Immunol; 2002; 15(3):451-71. PubMed ID: 12479395
[TBL] [Abstract][Full Text] [Related]
35. Biophysical characterization and single-chain Fv construction of a neutralizing antibody to measles virus.
Tadokoro T; Jahan ML; Ito Y; Tahara M; Chen S; Imai A; Sugimura N; Yoshida K; Saito M; Ose T; Hashiguchi T; Takeda M; Fukuhara H; Maenaka K
FEBS J; 2020 Jan; 287(1):145-159. PubMed ID: 31287622
[TBL] [Abstract][Full Text] [Related]
36. Recombinant NDV expressing cytokines or fliC confers a quick immune response against NDV challenge and resistance to maternal antibody.
Zhang T; Liu Y; Wang H; Zhang X; Zhu S; Xu P; Yin J; Ren G; Liu J; Li D
Vet Microbiol; 2016 Nov; 196():107-117. PubMed ID: 27939146
[TBL] [Abstract][Full Text] [Related]
37. Mucosal adenovirus-vectored vaccine for measles.
Lobanova LM; Baig TT; Tikoo SK; Zakhartchouk AN
Vaccine; 2010 Nov; 28(48):7613-9. PubMed ID: 20887832
[TBL] [Abstract][Full Text] [Related]
38. Vaccine-induced neutralizing antibodies bind to the H protein of a historical measles virus.
Zemella A; Beer K; Ramm F; Wenzel D; Düx A; Merkel K; Calvignac-Spencer S; Stern D; Dorner MB; Dorner BG; Widulin N; Schnalke T; Walter C; Wolbert A; Schmid BG; Mankertz A; Santibanez S
Int J Med Microbiol; 2024 Mar; 314():151607. PubMed ID: 38367508
[TBL] [Abstract][Full Text] [Related]
39. Differential induction of type I interferons in macaques by wild-type measles virus alone or with the hemagglutinin protein of the Edmonston vaccine strain.
Van Nguyen N; Kato SI; Nagata K; Takeuchi K
Microbiol Immunol; 2016 Jul; 60(7):501-5. PubMed ID: 27278100
[TBL] [Abstract][Full Text] [Related]
40. Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination.
Ota MO; Ndhlovu Z; Oh S; Piyasirisilp S; Berzofsky JA; Moss WJ; Griffin DE
J Infect Dis; 2007 Jun; 195(12):1799-807. PubMed ID: 17492596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
